Reports
The following list of reports reflects the latest in findings and outcomes in medical research as presented at major medical meetings and published peer-reviewed medical journals. In this section you can view reports from important congresses as well as summaries of some recently published journal articles. Please let us know if you have a particular area of interest you would like to see covered.
MEDICAL FRONTIERS - 23rd International Congress of the Transplantation Society
Perspective on Once-daily Immunosuppressive Therapy
Vancouver, British Columbia / August 15-19, 2010
Vancouver - Following organ transplantation, monitoring for optimal drug blood levels of immunosuppressive therapy is important, as lower levels may reduce efficacy while peaks in drug levels may carry an increased risk of toxicity. While a...
MEDICAL FRONTIERS - 2010 Congress of the European Renal Association and European Dialysis and Transplant Association (ERA-EDTA)
Controlling Hyperphosphatemia in Patients with Chronic Kidney Disease
Munich, Germany / June 25-28, 2010
Munich - Even between non-calcium-containing agents, phosphate binders used in dialysis patients appear to differ substantially. While these differences are now being closely evaluated for their influence on outcome, the attention generated...
JOURNAL CLUB - Transplantation
Immunosuppression for Kidney Transplant Recipients: Evidence-based KDIGO Practice Guidelines
June 2010
Based on The KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients. Am J Transplant 2009;9(suppl 3):S1-S155. IMMUNOSUPPRESSION FOR KIDNEY TRANSPLANT RECIPIENTS: EVIDENCE-BASED KDIGO PRACTICE GUIDELINES Editorial...
PRIORITY PRESS - American Transplant Congress 2010
Improving Long-term Outcomes in Kidney Transplant Recipients
San Diego, California / May 1-5, 2010
San Diego - The calcineurin inhibitors (CNIs) have long been the anchor of transplant immunosuppression, leading to low acute rejection rates in the short term. However, short-term gains have had little impact on long-term graft survival,...
PRIORITY PRESS - 30th Annual Meeting of the International Society of Heart and Lung Transplantation
Vasodilation to Reverse Complications Pre- and Post-heart Transplantation
Chicago, Illinois / April 21-24, 2010
Chicago - Phosphodiesterase type-5 (PDE-5) is abundantly expressed in the lungs. By selectively inhibiting the PDE-5 enzyme, PDE-5 inhibitors promote the accumulation of intracellular cyclic guanosine monophosphate, thereby enhancing nitric...
PRIORITY PRESS - 36th Annual Meeting of the European Group for Blood and Bone Marrow Transplantation (EBMT)
Progress in Infection Management of Allogeneic Stem Cell Recipients
Vienna, Austria / March 21-24, 2010
Vienna - In the last 10 years, widespread use of allogeneic hematopoietic stem cell transplantation has decreased the risk of recurrence in patients with aggressive hematological malignancies. However, the associated conditioning and...
PRIORITY PRESS - American Transplant Congress 2009
Preserving Organ Function with Non-CNI-Based Immunosuppressive Regimens
Boston, Massachusetts / May 30-June 3, 2009
Boston - Recognizing that calcineurin inhibitors (CNIs) may be nephrotoxic and/or diabetogenic, immunosuppressive protocols that minimize exposure to CNIs have gained acceptance in a variety of transplantation settings. Studies discussed...
PRIORITY PRESS - American Transplant Congress 2009
Outcomes in Kidney Transplant Recipients: Focus on Diabetes and BK-associated Nephropathy
Boston, Massachusetts / May 30-June 3, 2009
Boston - Short-term equivalency has been demonstrated for calcineurin inhibitors (CNIs) in widespread use today for prevention or treatment of graft rejection. Differences begin to emerge as outcomes are assessed over the longer term,...
PRIORITY PRESS - American Transplant Congress 2009
Immunosuppression in Liver Transplant Recipients
Boston, Massachusetts / May 30-June 3, 2009
Boston - Patients with hepatitis C (HCV) who undergo liver transplantation typically experience less favourable patient and graft survival compared with non-HCV liver transplant recipients, primarily because HCV frequently recurs, damaging...